PPD and Celtic Therapeutics Team Up
PPD (Wilmington, NC) has agreed to invest $100 million in Celtic Therapeutics Holdings, an investment partnership that identifies, acquires, and invests in midstage therapeutic candidates. The investment, according to a press release, sets the stage for a strategic alliance between Celtic Therapeutics and PPD, which will also perform clinical development services.
"Built upon the leadership and track records of Stephen Evans-Freke and Peter B. Corr, Celtic Therapeutics has a team of seasoned drug development professionals we believe is capable of building one of the most highly valued late-stage portfolios in the global biomedical industry," said Fred Eshelman, Executive Chairman of PPD.
For more information, click here.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
